Experts offer information and cancer centers take precautions in light of the novel coronavirus, and the Food and Drug Administration approves an immunotherapy combination for liver cancer.
The incidence of colorectal cancer – the fourth most common cancer diagnosed in the United States – has been steadily declining since the late 1990s. Despite this decrease, it is estimated that the lifetime risk of developing the disease is roughly one in 20 for those living in the United States. If the cancer is caught early when it is still localized, the five-year relative survival is almost 90 percent. However, if diagnosed after it has metastasized, the five-year relative survival is less than 15 percent.
The FDA approved using a combination of nivolumab and ipilimumab, two immune checkpoint inhibitors, to treat certain patients with hepatocellular carcinoma.
Multiple myeloma is a cancer of antibody-producing cells – called plasma cells – that accounts for approximately 1.8 percent of new cancer cases in the United States. Although it is a relatively uncommon cancer, those who are diagnosed face a five-year survival rate of only 52 percent. Patients who are diagnosed at an early stage generally have a better prognosis; however, almost all patients are diagnosed after the cancer has progressed to a more advanced stage.
A report shows that colorectal cancer incidence is decreasing in older adults while simultaneously rising in younger individuals, and more news of the week from Cancer Today.
Using an older method of prostate biopsy together with MRI-targeted biopsy more accurately diagnoses prostate cancer than either method alone, a study finds.
A highly complex filtering system, the kidneys process roughly half a cup of blood every minute, isolating waste and returning minerals and nutrients to the bloodstream. Renal cell carcinoma, a cancer that develops in the lining of the renal tubules, is the most common type of kidney cancer in adults, representing 85 percent of kidney and ureter cancers. Other types of kidney and ureter cancer can develop in the renal pelvis, the funnel where urine flows from the kidney to the bladder.
The FDA has approved a new therapeutic to treat adults with multiple myeloma whose cancer has progressed despite receiving at least two other treatments.
Researchers find a possible explanation for the link between certain gut bacteria and colorectal cancer and other cancer news of the week from Cancer Today magazine staff.
The FDA has expanded the use of the molecularly targeted therapeutic neratinib to include the treatment of certain patients with advanced or metastatic breast cancer
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More